Abstract
SMOKING CESSATION IS AN increasingly important area of focus for
pharmaceutical companies, healthcare entities and governments. There are 1.4
billion smokers in the world, and smoking is a known cause of heart disease,
lung cancer, respiratory infections and many other diseases. This has created
a large market for smoking cessation aids.
The market, which Zyban currently holds a tenuous lock on, is about to change,
with a major new brand ready to shake up the current market share. At the same
time, the high incidence of smoking and strong public-sector motivation to
reduce smoking signals room for new entrants.
The market for treatments for alcohol and drug abuse, now dominated by Subutex
and Campral, will also see growth and a robust line of new products.
Kalorama' s Smoking Cessation and Addiction Treatments: A World Market Analysis
covers the market for pharmaceuticals that assist with smoking cessation and
addiction treatment.
Using information gathered for Kalorama' s larger report on Psychotherapeutics:
the World Market and interviews with psychotherapeutic industry insiders
therein, this report takes a more detailed look at the combined market for
both smoking cessation and alcohol/drug addiction treatments. The report
includes:
- Round-up of current products available.
- Market share of major players and brands.
- Forecasted revenues to 2010.
- Forecasted Market Share with consideration of new players.
- Current revenues for 2005.
- World incidence data for Nicotine Addiction, Drug Addiction and Alcohol
Abuse.
- Reviews of new products in the pipeline.
- Key trends driving pharmaceutical treatments for smoking cessation and
drug addiction.
| 
View Cart
